Kevin Harrington, Professor in Biological Cancer Therapies at Institute of Cancer Research, shared Charleen Chan Wah Hak‘s post on LinkedIn, about an article Him and His collogues co-authored at AACR:
“Many congratulations, Charleen , for this excellent work in our lab shedding light on the reasons for the failure of the phase III TrilynX study of xevinapant in combination with chemoradiotherapy in patients with head and neck cancer.”
Quoting Charleen Chan Wah Hak‘s post on LinkedIn:
“Excited to share that a paper from my PhD research has been accepted by Cancer Research Communications (AACR Journals)!
Despite hugely promising data from a randomised phase II study, combined chemoradiotherapy plus xevinapant did not show benefit in the TrilynX Phase III trial for locally advanced head and neck squamous cell carcinoma. In our study, we demonstrate that the addition of xevinapant in vivo dysregulates anti-tumour lymphocyte function, acute phase proteins, and cell death pathways, resulting in net immunosuppressive effects on the tumour immune microenvironment. These findings may help explain the lack of clinical benefit observed.
A huge thank you to my supervisors, Prof Kevin Harrington and Prof Alan Melcher, my co-authors and the incredible team at the The Institute of Cancer Research for their guidance and support throughout this work.”
Title: Xevinapant plus chemoradiotherapy negatively sculpts the tumour immune microenvironment in head and neck cancer.
Authors: Charleen Chan Wah Hak, Emmanuel C. Patin, Anton Patrikeev, Annalisa Nicastri, Zuza Kozik, Holly Baldock, Joan N. Kyula-Currie, Victoria Roulstone, Amarin Wongariyapak, Valentina Gifford, Tencho Tenev, Elizabeth S. Appleton, Lisa C. Hubbard, Shane Foo, Malin Pedersen, Jyoti S. Choudhary, Masahiro Ono, Alan A. Melcher, Antonio Rullan, Kevin J. Harrington
Read the full article at AACR journal.
Read more posts featuring Kevin Harrington on OncoDaily.